Oliver Schon

Company: BiVictriX Therapeutics Ltd

Job title: VP, Research & Development

Seminars:

Leveraging Bi-Cygni Bispecific Antibody Drug Conjugates for High Selectivity Against Solid Tumors 8:30 am

An introduction to BiVictriX’s proprietary bispecific ADC approach in a solid tumor setting Reviewing shared from the lead solid tumor bispecific ADC program Observing tumor growth inhibition and tumor regressions observed at well-tolerated doses in a murine model of ovarian cancerRead more

day: Day One

Unlocking Strategies for Target Selection in Novel Conjugated Drugs 9:01 am

Selecting the right target is undeniably important for novel conjugate drugs as it plays into the efficacy, toxicity profile, and therapeutic window, ultimately determining whether this new modality is worth pursuing. Join this in-depth workshop to explore advanced strategies in target selection for the development of cutting-edge conjugated drugs, for novel targets as well as…Read more

day: Pre-Conference Workshop Day